Finance entity
All 1 tracked stories fall under one category: earnings. Of the tracked stories, 1 of 1 also mention FDA, the most common co-covered peer. Source depth averages 2 original sources per story, versus 2.6 across the same-window beat baseline. The 5 average consequence score is below the beat benchmark of 6 in the same window.
Last mentioned: Feb 26, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: earnings. Of the tracked stories, 1 of 1 also mention FDA, the most common co-covered peer. Source depth averages 2 original sources per story, versus 2.6 across the same-window beat baseline. The 5 average consequence score is below the beat benchmark of 6 in the same window. We currently track 1 Finance story that mention Acclarent, all published on February 26, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 120 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Acclarent. Shared-story counts are live from our verified record — not editorial picks.
Q4 2025 Earnings
Company reports results and provides 2026 guidance, signaling continued remediation efforts.
Projected Restart
Target window for the commercial re-launch of SurgiMend and PriMatrix products.
New Leadership
Mojdeh Poul assumes role as CEO to lead the company's quality and operational turnaround.
Boston Recall
Integra initiates voluntary recall of all products manufactured in Boston due to endotoxin concerns.
Integra LifeSciences (IART) shares faced downward pressure following its Q4 2025 earnings call, as management detailed an extended timeline for its Boston facility restart and the ongoing costs of its Quality Excellence Program. While the company provided its first full-year 2026 guidance, investor caution remains high regarding the path to normalized growth and product re-launches.
Acclarent is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
